A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

Launched by CENTURY THERAPEUTICS, INC. · Mar 3, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the long-term safety and survival of people who have previously received a specific type of treatment called cellular therapy for blood cancers (hematological malignancies) or solid tumors. The study is observational, meaning researchers will follow participants to monitor how they are doing over time and check for any health issues that might arise after their initial treatment. By collecting this information, the trial aims to identify any long-term risks or side effects related to the cellular therapy.

To participate, individuals need to be between 65 and 74 years old and must have already been treated with a cellular therapy product in a previous study. They should also be able to attend follow-up visits and agree to the study procedures. Importantly, there are no specific exclusion criteria, so most participants are welcome as long as they meet these basic requirements. Those who join can expect regular check-ins and opportunities to share their health experiences, helping to improve understanding of the effects of cellular therapy over time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant has provided written informed consent prior to any long-term follow-up (LTFU) study-specific procedures.
• • Participants received at least one treatment with a cellular therapy product in an eligible index trial.
• • Participant was withdrawn, early discontinued or completed an eligible index trial.
• • Participant is willing and able to comply with scheduled visits, study plan, and other study procedures.
• Exclusion Criteria:
• • -This study has no exclusion criteria.